Brenus Pharma
Summary active Updated Jul 22, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Brenus Pharma is a Lyon, France-based clinical-stage biotech developing an off-the-shelf platform for novel immuno-oncology modalities that mimic tumor protein expression to enable multi-specific in vivo immune responses against hard-to-treat solid tumors 123. The company’s lead candidate STC-1010 is a Phase I in-vivo immunotherapy for metastatic MSS colorectal cancer (mCRC) 123. On 2026-07-20 Brenus announced an €11 million ($12.6M) Series A extension bringing total capital raised since inception to €38 million ($43.5M) 123. The extension was supported by follow-on participation from existing investors Angelor, UI Investissement (managing FRAI), Crédit Agricole (CACE Création, CACF Capital Innovation), Noshaq, Orsa (formerly Investsud), BIO JAG, and Bpifrance (through non-dilutive funding), and welcomed two new international investors: Sambrinvest (strengthening the company’s European shareholder base) and Korea Omega Investment Corp, marking Brenus’ first institutional investment from the Asia-Pacific region 123.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-20 | Series A Extension | €11M | (undisclosed lead) | Angelor, UI Investissement, Crédit Agricole (CACE Création, CACF Capital Innovation), Noshaq, Orsa, BIO JAG, Bpifrance, Sambrinvest, Korea Omega Investment Corp 123 |
What Investors Say
“We couldn’t be more confident in our first investment in France. Brenus Pharma exemplifies exactly the type of European innovation we want to support.” — Dae Kyeong Bae, Korea Omega Investment Corp, Brenus Pharma press release, 2026-07-20 1.
What Founders Say
No independently sourced founder testimonials with direct quotes found at time of publication.
Sources
-
“Brenus Pharma Welcomes New European and Asia-Pacific Life Sciences Investors in Series A Extension,” BioSpace / BusinessWire press release, July 20, 2026. Accessed July 2026. https://www.biospace.com/press-releases/brenus-pharma-welcomes-new-european-and-asia-pacific-life-sciences-investors-in-series-a-extension↩↩↩↩↩↩↩
-
“Brenus Pharma Raises €11M in Series A Extension Funding,” FinSMEs, July 20, 2026. Accessed July 2026. https://www.finsmes.com/2026/07/brenus-pharma-raises-e11m-in-series-a-extension-funding.html↩↩↩↩↩↩
-
“Brenus adds €11M to colorectal cancer vaccine development,” European Biotechnology Magazine, July 2026. Accessed July 2026. https://european-biotechnology.com/latest-news/brenus-extension-series-a-colorectal-cancer-vaccine/↩↩↩↩↩